DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinal Muscular Atrophy market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Spinal Muscular Atrophy: An Overview
According to the National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons, that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). Muscle weakness usually worsens with age.
Spinal Muscular Atrophy is a motor neuron disease caused by a Bi-allelic mutation of survival motor neuron gene 1 (SMN1). There are two identical genes, SMN1 (telomeric copy) and SMN2 (centromeric copy), present in human chromosome 5q13. These genes are responsible for synthesizing survival motor neuron protein, which is necessary for the normal function of motor neurons that control our muscles. The insufficient production of SMN proteins leads to debilitating and often fatal muscle weakness.
Spinal Muscular Atrophy Market Key Facts
The total prevalent population of Spinal Muscular Atrophy (SMA) in the seven major markets was 19,300+ in 2017.
As per the estimates among the EU5 countries, Germany had the highest prevalent population of Spinal Muscular Atrophy, with 1,600+ cases in 2017, followed by the UK and France. On the other hand, Spain had the lowest prevalence, with 400+ cases in 2017.
As per DelveInsight analysis, the diagnosed prevalent cases of Spinal Muscular Atrophy in the United States were found to be 11,700+ in 2017.
As per the study by B. Melissa et al. (2017), Spinal muscular atrophy (SMA) is the most common genetic disease resulting in infant death, affecting approximately 1 in 6,000 to 1 in 10,000 births. Therapies that improve neuromuscular function and maintain the lifelong general health of people living with SMA are a major priority and unmet clinical need.
The emerging pipeline of Spinal Muscular Atrophy has a few promising lead candidates in various stages of development, which are yet to be launched. The potential candidates with promising results include Apitegromab (Scholar Rock), GYM329 (Roche), and others.
Spinal Muscular Atrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Spinal Muscular Atrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Spinal Muscular Atrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Spinal Muscular Atrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Spinal Muscular Atrophy Epidemiology Segmented by –
Age-specific Prevalence of Spinal Muscular Atrophy
Type-specific Prevalence of Spinal Muscular Atrophy
Total Prevalent Population of Spinal Muscular Atrophy
Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to get launched during the study period. The analysis covers the Spinal Muscular Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Spinal Muscular Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Spinal Muscular Atrophy Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market
Spinal Muscular Atrophy Therapeutics Analysis
Treatment of Spinal Muscular Atrophy is quite challenging. However, from an overall perspective, recent and extensive research and development activities being conducted for developing novel drugs, increased understanding of the related comorbidities, and the upcoming pipeline drug launches are expected to create a lucrative environment for the Spinal Muscular Atrophy treatment market to grow in the coming years.
The Spinal Muscular Atrophy pipeline possesses multiple potential drugs in late and mid-stage developments that are expected to be launched in the near future.
Some of the key companies developing therapies for the treatment of Spinal Muscular Atrophy include:
Novartis
Cytokinetics
Astellas
Biogen
Hoffmann-La Roche
PTC Therapeutics
Catalyst Pharmaceuticals
Scholar Rock
And Many More
Spinal Muscular Atrophy Therapies covered in the report include:
BVS 857
SRK-015
Branaplam (LMI070)
Reldesemtiv (CK-2127107)
Amifampridine Phosphate (Firdapse)
Apitegromab
GYM329
And Many Others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Spinal Muscular Atrophy Competitive Intelligence Analysis
4. Spinal Muscular Atrophy Market Overview at a Glance
5. Spinal Muscular Atrophy Disease Background and Overview
6. Spinal Muscular Atrophy Patient Journey
7. Spinal Muscular Atrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinal Muscular Atrophy Unmet Needs
10. Key Endpoints of Spinal Muscular Atrophy Treatment
11. Spinal Muscular Atrophy Marketed Products
12. Spinal Muscular Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Spinal Muscular Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Spinal Muscular Atrophy Market Outlook (In US, EU5, and Japan)
16. Spinal Muscular Atrophy Access and Reimbursement Overview
17. KOL Views on the Spinal Muscular Atrophy Market
18. Spinal Muscular Atrophy Market Drivers
19. Spinal Muscular Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
Spinal Muscular Atrophy (SMA) Pipeline Insights
“Spinal Muscular Atrophy Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ drugs in the Spinal muscular atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
